Results 1 to 10 of about 564,114 (160)

Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid [PDF]

open access: yesAnnals of Medicine, 2023
Aim: Bullous pemphigoid (BP) is an organ-specific autoimmune bullous disease characterized by autoantibodies that target the cellular adhesion molecules BP180 and BP230.
Fangyuan Chen   +4 more
doaj   +2 more sources

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis [PDF]

open access: yesPharmaceutics, 2023
Atopic dermatitis (AD) is a common chronic inflammatory skin condition that has a significant impact on a patient’s quality of life and requires ongoing management.
Yuliya Lytvyn, Melinda Gooderham
doaj   +2 more sources

Interleukin 13 Promotes Maturation and Proliferation in Metaplastic GastroidsSummary [PDF]

open access: yesCellular and Molecular Gastroenterology and Hepatology
Background & Aims: Type 2 innate lymphoid cells (ILC2s) and interleukin-13 (IL-13) promote the onset of spasmolytic polypeptide-expressing metaplasia (SPEM) cells. However, little is known about molecular effects of IL-13 in SPEM cells. We now sought
Ela W. Contreras-Panta   +8 more
doaj   +2 more sources

Interleukin-13 and age-related macular degeneration [PDF]

open access: yesInternational Journal of Ophthalmology, 2017
AIM: To identify the effects of interleukin (IL)-13 on retinal pigment epithelial (RPE) cells and the IL-13 level in aqueous humor of age-related macular degeneration (AMD) patients.
Bo Fu, Zhe-Li Liu, Han Zhang, Feng Gu
doaj   +3 more sources

Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy

open access: yesCells, 2021
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. SSc causes damage to the skin and various organs including the lungs, heart, and digestive tract, but the extent of the damage varies from patient to patient.
Yoshihito Shima
doaj   +1 more source

Selective IL-13 inhibitors for the treatment of atopic dermatitis

open access: yesDrugs in Context, 2021
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves   +2 more
doaj   +1 more source

Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis

open access: yesFrontiers in Immunology, 2023
BackgroundFibrostenotic disease is a common complication in Crohn’s disease (CD) patients hallmarked by transmural extracellular matrix (ECM) accumulation in the intestinal wall.
Kristina Koop   +19 more
doaj   +1 more source

Association of interleukin-13 gene variants with susceptibility to brucellosis [PDF]

open access: yesTrends in Pharmaceutical Sciences, 2016
Brucella is an intracellular Gram-negative bacterium. Previous reports showed that gene polymorphisms of cytokines can affect resistance or susceptibility to Brucella infection.
Sayed-Jalal-Aladin Ashraf-Mansuri   +5 more
doaj   +2 more sources

Mutants of Interleukin 13 with Altered Reactivity toward Interleukin 13 Receptors [PDF]

open access: yesJournal of Biological Chemistry, 1999
Interleukin 13 (IL13) belongs to a family of cytokines whose members exhibit structural homology, despite amino acid sequence dissimilarity. For example, while of limited sequence homology, IL13 and IL4 share a signaling receptor, IL13/4 receptor, on a variety of human normal cells. However, a subclass of IL4-independent IL13 receptors is overexpressed
J P, Thompson, W, Debinski
openaire   +2 more sources

Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis

open access: yesViruses, 2020
Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
John Foerster, Aleksandra Molęda
doaj   +1 more source

Home - About - Disclaimer - Privacy